STOCK TITAN
  1. Home
  2. Sec-filings
  3. EVAX
  4. [6-K] Evaxion A/S Current Report (Foreign Issuer)

Evaxion (NASDAQ: EVAX) earns 2026 Prix Galien UK digital health honor

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company, reports that its AI-Immunology™ platform has received the 2026 Prix Galien UK Award for Best digital health solution. The prize recognizes the platform’s use of artificial intelligence to decode the human immune system and generate novel vaccine candidates for cancer and infectious diseases.

This is Evaxion’s second recognition from the Galien Prix Foundation in less than a year, following a December 2025 award for Best Medical Technology / AI Advances in Nordic and high-growth regions. The UK award was decided by a committee of 12 scientific leaders, who evaluated innovation, clinical application, scientific insights and impact on human health.

Positive

  • None.

Negative

  • None.
Award 2026 Prix Galien UK Award Best digital health solution for AI-Immunology™
Number of candidates for award 10 candidates AI-Immunology™ selected among 10 candidates
Awards committee size 12 experts Prix Galien UK Awards Committee membership
Prior Galien recognition date December 2025 Earlier award for Best Medical Technology / AI Advances
Products honored since inception 62 products Prix Galien Awards history since establishment
Team size More than 40 experts Evaxion team across discovery to clinical development
AI-Immunology™ technical
"developing novel vaccines with its pioneering AI-Immunology™ platform"
ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.
TechBio technical
"a clinical-stage TechBio company developing novel vaccines"
A techbio company uses advanced engineering, computing and data tools together with biology to design or make new medicines, diagnostics, or bio-based products. For investors, it signals a blend of lab science and software-style innovation: potential for rapid scaling and platform value but also higher research costs, longer development timelines, and technical risk—similar to backing an engineering-driven startup applied to living systems.
Prix Galien UK Award other
"has been awarded the 2026 Prix Galien UK Award for Best digital health solution"
forward-looking statements regulatory
"This announcement contains forward-looking statements within the meaning of Section 27A"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
clinical-stage financial
"Evaxion A/S, a clinical-stage TechBio company"
Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On June 12, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion receives Prix Galien UK Award for Best digital health solution". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit Number Description
   
99.1 Evaxion receives Prix Galien UK Award for Best digital health solution

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   Evaxion A/S
   (Registrant)
    
   
Date: June 12, 2026 By:/s/ Helen Tayton-Martin    
   Helen Tayton-Martin
   Chief Executive Officer
   

EXHIBIT 99.1

Evaxion receives Prix Galien UK Award for Best digital health solution

COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien UK Award for Best digital health solution for AI-Immunology™.

The award is another strong external validation and recognition of the AI-Immunology™ platform, which harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

The award was received by Evaxion CEO Helen-Tayton Martin at the Prix Galien UK Awards ceremony at the Natural History Museum in London. Evaxion and AI-Immunology™ was chosen by a committee of distinguished scientific leaders among 10 candidates.

“We are honored to receive this distinction, which rewards the unique capabilities of AI-Immunology™ in effective vaccine target discovery, design and development. We are even more proud since this is the second recognition from the Galien Prix Foundation in less than a year. This kind of external validation is a great boost to our efforts to continuously improve AI-Immunology™ and bring forward safe and effective vaccine candidates in cancer and infectious disease,” says Helen Tayton-Martin.

In its evaluation, the jury focused on the innovation demonstrated throughout each candidate’s scientific development, clinical application, and utility. Further consideration was given to the insights it has advanced in biomedical science and the product's tangible impact on human health.

This is not the first time Evaxion has been recognized by the Galien Prix Foundation. In December 2025, we received the award for the Best Medical Technology / AI Advances in the Nordic and high-growth European and Middle Eastern countries.

The Prix Galien Awards were established in 1970 and launched in the UK in 1990 and have been awarded to 62 products since inception. Winners are selected every year by the Prix Galien UK Awards Committee, which comprises 12 experts in the field, and includes a number of the UK's leading luminaries in healthcare. The distinguished panel is guided by the conviction that acknowledging research-driven innovation is key to the improvement of healthcare in the UK and human health, globally.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Source: View Original Filing on SEC EDGAR

FAQ

What award did Evaxion (EVAX) announce in its June 2026 Form 6-K?

Evaxion announced it received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform. The prize honors research-driven innovation with meaningful impact on healthcare and human health, recognizing Evaxion’s AI-driven vaccine discovery approach.

Why is the Prix Galien UK Award important for Evaxion (EVAX)?

The Prix Galien UK Award is a prestigious recognition judged by 12 leading healthcare experts. It highlights AI-Immunology™ for scientific innovation, clinical utility, and impact on human health, providing notable external validation of Evaxion’s platform-driven vaccine development strategy.

What is Evaxion’s AI-Immunology™ platform as described in the filing?

AI-Immunology™ is Evaxion’s proprietary AI platform designed to decode the human immune system and identify vaccine targets. It supports rapid, efficient target discovery, drug design and development for personalized and off‑the‑shelf cancer vaccines and prophylactic vaccines against infectious diseases.

What kind of pipeline does Evaxion (EVAX) report in this Form 6-K?

Evaxion reports a clinical pipeline that includes both personalized and off‑the‑shelf cancer vaccine candidates, along with prophylactic vaccines for infectious diseases. All candidates target areas of high unmet medical need, aligning with the company’s focus on innovative, AI-driven immunotherapies.

How large is the Evaxion (EVAX) team supporting AI-Immunology™?

Evaxion notes that a team of more than 40 experts supports AI-Immunology™. These professionals span the value chain from target discovery through clinical development, underpinning the company’s ability to turn AI-derived insights into clinical-stage vaccine candidates.

Filing Exhibits & Attachments

1 document

Press Releases